Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 6/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 3/20 | 0.37 |
| ▸ | CCND1 | P24385 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29672392 | 1.00 | PRKDC (0.42) | PRKDCTDP1KDM4EMEN1NPC1 | |
| SCHEMBL10869453 | 0.78 | CHEK1 (0.38) | KDM4EMEN1GAAKMT2APARP1 | |
| SCHEMBL1652391 | 0.77 | IDO1 (0.53) | PRKDCTDP1KDM4EMEN1NPC1 | |
| SCHEMBL30140376 | 0.77 | IDO1 (0.53) | PRKDCTDP1KDM4EMEN1NPC1 | |
| SCHEMBL31190839 | 0.76 | ALKBH5 (0.41) | PRKDCTDP1KDM4EMEN1NPC1 | |
| SCHEMBL4512211 | 0.76 | ALKBH5 (0.41) | PRKDCTDP1KDM4EMEN1NPC1 | |
| SCHEMBL18161340 | 0.75 | PRKDC (0.44) | PRKDCTDP1KDM4EMEN1NPC1 | |
| SCHEMBL877668 | 0.73 | IDO1 (0.41) | PRKDCTDP1KDM4EMEN1NPC1 | |
| SCHEMBL15829323 | 0.73 | PARP1 (0.50) | PRKDCKDM4ENPC1MAPTKMT2A | |
| SCHEMBL30050610 | 0.73 | IDO1 (0.41) | PRKDCTDP1KDM4EMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176595-A1 | Glucocorticoid receptor modulators | PFIZER, INC. | 2004-09-09 | — | — | US | claimed |
| US-20020147336-A1 | Glucocorticoid receptor modulators | DOW ROBERT L (US) | 2002-10-10 | — | — | US | claimed |
| WO-2015197550-A1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2015-12-30 | — | — | WO | disclosed |
| US-7166593-B2 | Glucocorticoid receptor modulators | PFIZER, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20040176353-A1 | Derivatives of pyrimido[6,1-a]isoquinolin-4-one | VERNALIS LIMITED | 2004-09-09 | — | — | US | disclosed |
| US-20040176595-A1 | Glucocorticoid receptor modulators | PFIZER, INC. | 2004-09-09 | — | — | US | disclosed |
| US-6699893-B2 | DIETETICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATROY AGENTS | PFIZER INC | 2004-03-02 | — | — | US | disclosed |
| US-20020147336-A1 | Glucocorticoid receptor modulators | DOW ROBERT L (US) | 2002-10-10 | — | — | US | disclosed |
| US-6380223-B1 | FOR THERAPY OF DISEASES, SUCH AS OBESITY, DIABETES, INFLAMMATION | PFIZER INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1175383-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | Pfizer Products Inc. (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066522-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | PFIZER PRODUCTS INC. (US) | 2000-11-09 | — | — | WO | disclosed |
| EP-0417143-A1 | CYCLIC LACTAMS FOR CHOLESTEROL AND ATHEROSCLEROSIS CONTROL | THE UPJOHN COMPANY (US) | 1991-03-20 | — | — | EP | disclosed |
| WO-1989011856-A2 | CYCLIC LACTAMS FOR CHOLESTEROL AND ATHEROSCLEROSIS CONTROL | THE UPJOHN COMPANY (US) | 1989-12-14 | — | — | WO | disclosed |
| EP-0183994-A1 | Tricyclic pyridone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176595-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | PRKDC 4859/4885TDP1 4800/4885KDM4E 2685/4885 |
| US-20020147336-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | PRKDC 4858/4885TDP1 4791/4885KDM4E 2743/4885 |
| US-20040176353-A1 | Derivatives of pyrimido[6,1-a]isoquinolin-4-one | TAS1R2, TAS2R1, TAS2R7 | PRKDC 3578/4885TDP1 1446/4885KDM4E 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.